Evaluation of the Diagnostic of Hepatic Fibrosis With the in Severe Obese Patients Candidates to Bariatric Surgery

European Georges Pompidou Hospital132 enrolled

Overview

Background: The XL probe of FibroScan was recently developed to realize liver stiffness measurements (LSM) in overweight patients. Severe obese patients have a high prevalence of liver injuries and could benefit of liver evaluation prior to bariatric surgery. Objectives: Assess the FibroScan applicability, reliability and diagnostic performances in severe obese patients' candidates for bariatric surgery.

Study Type

OBSERVATIONAL

Enrollment

132

Conditions

Steatosis Obesity Fibrosis, Liver

Interventions

Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric SurgeryDEVICE

Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Severe obese patients candidate to bariatric surgery with no history of liver disease have a large prevalence of liver lesions.

Outcomes

Primary Outcomes

Elasticity measured with the Fibroscan XL

Liver elasticity will be measured non-invasively with Fibroscan. As this is a non-invasive measure, no adverse effects are expected. No treatment planned.

Time frame: 3 years

Secondary Outcomes

53/5000 Evolution of elasticity after bariatric surgery

The evolution of elasticity will be measured non-invasively with fibroscan after bariatric surgery. NO adverse effects are expected in relation to this measure.

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.